Mark L. Pacala
Director · Starling Oncology, Inc.
IndividualSelling only
- 2024
- Jul 29, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Mark L. Pacala files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Jorey Chernett - $2.69M in STLN purchases and sales in the last 12 months
- Brad Hively - $2.00M in STLN purchases and sales in the last 12 months
- Mohit Kaushal - $335K in STLN purchases and sales in the last 12 months
- Yale Podnos - $276K in STLN purchases and sales in the last 12 months
- Robert Ross Carter - $879 in STLN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Mark L. Pacala?
Mark L. Pacala is a corporate insider, tracked as Director of Starling Oncology, Inc. (STLN). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Mark L. Pacala submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Mark L. Pacala been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($200K) across all tracked filings.
